SALT LAKE CITY, Dec. 12, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the myRisk Hereditary Cancer test found 51 percent more patients with a higher risk of hereditary breast and ovarian cancer than did testing for the BRCA1 and BRCA2 genes alone. myRisk is a new diagnostic test that uses next-generation sequencing technology to evaluate 25 genes associated with eight major hereditary cancers including: breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric and melanoma.
This large prospective clinical validation study measured mutations in 25 cancer-causing genes among patients who were referred for BRCA1/2 testing. Among the 1,951 patients evaluated, 275 patients tested positive for a deleterious mutation with the myRisk test. Testing only for the BRCA1 and BRCA2 genes found only 182 of the mutation carriers, representing a 51 percent increase in hereditary breast and ovarian cancer mutation detection for the myRisk test. In this study, the accuracy of the myRisk test was 99.99 percent.
myRisk Hereditary Cancer has now been validated in approximately 5,000 patients in clinical studies. Today's results build on recently presented data that showed the myRisk test improved the detection of mutations in patients referred for hereditary colon cancer testing by 61 percent and with a 99.99 percent accuracy, which is equal to the gold standard Sanger DNA sequencing."Hereditary cancers are caused by mutations in many different genes and new genes linked to cancer have been recently identified. Testing only for one hereditary cancer syndrome may lead to missed mutations," said Richard J. Wenstrup, M.D., chief medical officer of Myriad. "The myRisk test evaluates 25 clinically actionable genes and significantly improves our ability to identify people at higher risk for hereditary cancer, which may lead to prevention or early detection with the ability to reduce cancer incidence and mortality."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV